780763-91-9

Upstream product

• 67-56-1 methanol 
• 39695-96-0 2-(4-nitrophenyl)ethanimidamide hydrochloride 
• 6279-86-3 methanetricarboxylic acid triethyl ester 
• 124-41-4 sodium methylate 
• 40967-67-7 trimethyl ethane-1,1,2-tricarboxylate 
• 7459-46-3 triethyl 1,1,2-ethanetricarboxylate 
• 555-21-5 4-Nitrophenylacetonitrile 

Downstream Products

• 780763-92-0 [4,6-dichloro-2-(4-nitrobenzyl)pyrimidin-5-yl]acetic acid methyl ester 
• 1214271-93-8 methyl [4,6-bis([(2H)6]dimethylamino)-2-(4-nitrobenzyl)pyrimidin-5-yl]acetate 
• 1214271-94-9 methyl [2-(4-aminobenzyl)-4,6-bis([(2H)6]dimethyl-amino)pyrimidin-5-yl]acetate 
• 1214271-95-0 methyl [4,6-bis([(2H)6]dimethylamino)-2-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)pyrimidin-5-yl]acetate 
• 1214271-89-2 [4,6-bis([(2H)6]dimethylamino)-2-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)pyrimidin-5-yl]acetic acid 
• 1093108-50-9 actimis 
• 1413122-69-6 [4,6-bis-dimethylamino-2-(4-nitrobenzyl)pyrimidin-5-yl]acetic acid methyl ester 
• 1413122-72-1 [4,6-bisdimethylamino-2-(4-aminobenzyl)pyrimidin-5-yl]acetic acid methyl ester 
• 1413122-74-3 [4,6-bisdimethylamino-2-[4-(4-trifluoromethylbenzoylamino)benzyl]pyrimidin-5-yl]acetic acid methyl ester 
• 780765-24-4 methyl [4-methyl-2-[4-(2-naphthoylamino)benzyl]-6-(1-pyrrolidinyl)-5-pyrimidinyl]acetate 
• 1362050-48-3 methyl [4-chloro-2-{4-[(4-chlorobenzoyl)(methyl)amino]benzyl}-6-(dimethylamino)-5-pyrimidinyl]acetate 
• 1362050-56-3 methyl {4-(dimethylamino)-2-[4-(2-naphthoylamino)benzyl]-5-pyrimidinyl}acetate 
• 780765-23-3 methyl [4-methyl-2-(4-nitrobenzyl)-6-(1-pyrrolidinyl)-5-pyrimidinyl]acetate 
• 1362050-35-8 methyl [2-(4-aminobenzyl)-4-methyl-6-(1-pyrrolidinyl)-5-pyrimidinyl]acetate 

Relevant academic research and scientific papers

PROCESS FOR PREPARING [4,6-BIS-DIMETHYLAMINO-2-[4-(4-TRIFLUOROMETHYLBENZOYL-AMINO)BENZYL]PYRIMIDIN-5-YL]ACETIC ACID

The present invention relates to a process for preparing a compound of formula (I).

ISOTOPICALLY ENRICHED PYRIMIDIN-5-YL ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS

Provided herein are 2H- and 13C-enriched compounds of formula (I) or (II); wherein R is as defined herein, and wherein at least one hydrogen atom, in certain embodiments, three or more hydrogen atoms, are deuterium atoms or at least one carbon atom is a carbon-13 atom. Also provided are pharmaceutical compositions and methods using the 2H- and 13C-enriched compounds, useful for treating CRTH2-related diseases or disorders such as, for example, asthma, allergic rhinitis, atopic dermatitis, allergic conjuvatitis, Churg-Strauss syndrome, sinusitis, basophilic leukemia, chronic urticaria or basophilic leukocytosis.

IMIDAZO[1,2-C]PYRIMIDINYLACETIC ACID DERIVATIVES

The present invention relates to an imidazo[1,2-c]pyrimidinylacetic acid derivative and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The imidazo[1,2-c]pyrimidinylacetic acid derivative of the present invention has

Pyrimidinylacetic acid derivatives useful for the treatment of diseases mediated by CRTH2

The present invention relates to a pyrimidinylacetic acid derivative of formula (1) wherein R1-R4 is defined herein, and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The pyrimidinylacetic acid derivative of the present invention has excellent CRTH2 (G-protein-coupled chemoattractant receptor, expressed on Th2 cells) antagonistic activity and can be used for the prophylaxis and treatment of diseases associated with CRTH2 activity, in particular for the treatment of allergic diseases, such as ashtma, allergic rhinitis and allergic conjunctivitis; eosinophil-related diseases, such as Churg-Strauss syndrome and sinusitis; and basophil-related diseases, such as basophilic leukemia, chronic urticaria and basophilic leukocytosis in human and other mammals.